Kardigan priced 25,000,000 shares at $16.00 for $400,000,000 before fees. The company says the proceeds fund operations into 2028, yet its prospectus warns of substantial doubt about its ability to continue as a going concern.
Kardigan filed an S-1 for an IPO that would list on the Nasdaq Global Market as KARD. The filing leaves the share count and price range blank, reports $287.1 million of cash and investments, and still says there is substantial doubt about its ability to continue as a going concern.
Questions about Kardigan
Has Kardigan issued a going-concern warning?
Our latest story on this, dated Jun 18, 2026: "Kardigan prices IPO of 25,000,000 shares at $16.00". The story links the filing or release it is based on. Read the story.
When did Kardigan go public?
Our latest story on this, dated Jun 18, 2026: "Kardigan prices IPO of 25,000,000 shares at $16.00". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Kardigan?
Kardigan, Inc. trades under the ticker KARD on NASDAQ.
Where is Kardigan listed?
Kardigan, Inc. is listed on NASDAQ.
What is the SEC CIK of Kardigan?
The SEC Central Index Key (CIK) for Kardigan, Inc. is 2123613. Its filings are on SEC EDGAR.
How many shares does Kardigan have outstanding?
93,503,699 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-11.
Which country or territory is Kardigan listed under?
Our directory records Kardigan, Inc. under United States.
What does Kardigan do?
Our directory classifies Kardigan, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Kardigan?
The ISIN recorded for Kardigan, Inc. is US4859251013.
Does aibio.space cover Kardigan?
aibio.space lists Kardigan, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Kardigan incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest Kardigan (KARD) stock news?
Our latest story on Kardigan, dated Jun 18, 2026: "Kardigan prices IPO of 25,000,000 shares at $16.00". Kardigan priced 25,000,000 shares at $16.00 for $400,000,000 before fees. The company says the proceeds fund operations into 2028, yet its prospectus warns of substantial doubt about its ability to continue as a going concern. Source.
What is Kardigan's latest stock offering or financing news?
Our latest financing story, dated Jun 18, 2026: "Kardigan prices IPO of 25,000,000 shares at $16.00". Kardigan priced 25,000,000 shares at $16.00 for $400,000,000 before fees. The company says the proceeds fund operations into 2028, yet its prospectus warns of substantial doubt about its ability to continue as a going concern. Source.
Who were the underwriters or placement agents on Kardigan's offering?
From our story: J.P. Morgan, Jefferies, Leerink Partners and TD Cowen are named on the cover as underwriters. Source.
How long will Kardigan's cash last?
From our story of Jun 18, 2026: The company says the proceeds fund operations into 2028, yet its prospectus warns of substantial doubt about its ability to continue as a going concern. Source.
Investor discussion: Kardigan
Members talk about Kardigan (KARD). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Kardigan, newest first. Each line links the filing it comes from.
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:KARD on TradingView.
SEC filings and registration
SEC name
Kardigan, Inc.
CIK
2123613
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
KARD (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
C/O KARDIGAN, INC., SOUTH SAN FRANCISCO, CA, 94080
Phone
(415) 573-3220
Shares outstanding
93,503,699 as of 2026-08-07 (10-Q filed 2026-08-11)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Kardigan, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KARD, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio